Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease

International Journal of Clinical Practice

Volumn 64, Issue 5, 2010, Pages 651-660

  Grossberg, G T ^a   Sadowsky, C ^b   Olin, J T ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; CHEMISTRY; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCIDENCE; INJECTION SITE REACTION; IRRITANT DERMATITIS; MEDICAL INFORMATION; MEDLINE; NAUSEA; OPEN STUDY; PARKINSON DISEASE; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PUBLICATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN ALLERGY; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, CUTANEOUS; ALZHEIMER DISEASE; HUMANS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 77949383588     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02330.x     Document Type: Review

References (60)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's Demen 2009; 5: 234-70.
2. Hebert LE, Scherr PA, Bienias JL et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22.
3. Connell CM, Janevic MR, Gallant MP. The costs of caring: impact of dementia on family caregivers. J Geriatr Psychiatry Neurol 2001; 14: 179-87.
4. Aupperle PM. Navigating patients and caregivers through the course of Alzheimer's disease. J Clin Psychiatry 2006; 67(Suppl. 3): 8-14. Quiz 23.
5. Förstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 288-90.
6. Reisberg B, Franssen E, Souren L, Cespon R. Alzheimer's disease. In: Eisenberg M, Glueckauf R, Zaretsky H, eds. Medical Aspects of Disability: A Handbook for the Rehabilitation Professional, 2nd edn. New York, NY: Springer Publisher Company, 1999: 68-97.
7. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-66.
8. Knopman D, Donohue JA, Gutterman EM. Patterns of care in the early stages of Alzheimer's disease: impediments to timely diagnosis. J Am Geriatr Soc 2000; 48: 300-4.
9. Werner P. Knowledge about symptoms of Alzheimer's disease: correlates and relationship to help-seeking behavior. Int J Geriatr Psychiatry 2003; 18: 1029-36.
10. Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-53.
11. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003; 51: 1451-4.
12. Buschke H, Kuslansky G, Katz M et al. Screening for dementia with the memory impairment screen. Neurology 1999; 52: 231-8.
13. Brodaty H, Pond D, Kemp NM et al. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 2002; 50: 530-4.
14. Birks J, Grimley Evans J, Iakovidou V et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009: 2: CD001191.
15. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
16. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
17. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7.
18. Whitehouse PJ, Price DL, Struble RG et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9.
19. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999; 12: 307-23.
20. Nitti VW, Sanders S, Staskin DR et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006; 67: 657-64.
21. Petersen TA. Transdermal drug formulations and process development. Pharm Technol 2003; (Suppl.): 18-21.
22. Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008; 5: 1377-86.
23. Mercier F, Lefèvre G, Huang HL et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007; 23: 3199-204.
24. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
25. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-39.
26. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 1998; 13: 391-411.
27. Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1056-63.
28. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69: (Suppl. 1) S10-3.
29. Lefèvre G, Sȩdek G, Jhee S et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008; 83: 106-14.
30. Grossberg GT, Stahelin HB, Messina JC et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000; 15: 242-7.
31. Exelon Patch®. US Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009.
32. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
33. Schneider LS, Olin JT, Doody RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11: (Suppl. 2) S22-32.
34. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl. 2): S33-9.
35. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
36. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
37. Watson YI, Arfken CL, Birge SJ. Clock completion: an objective screening test for dementia. J Am Geriatr Soc 1993; 41: 1235-40.
38. Corrigan JD, Hinkeldey NS. Relationships between parts A and B of the trail making test. J Clin Psychol 1987; 43: 402-9.
39. Winblad B, Grossberg G, Frölich L et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69(Suppl. 1): S14-22.
40. Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-91.
41. Blesa R, Ballard C, Orgogozo J-M et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69(Suppl. 1): S23-8.
42. Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgemont) 2008; 5: 27-36.
43. Levin C, Maibach H. Transdermal drug delivery system: an overview. In: Zhai H, Maibach H, eds. Marzulli and Maibach's Dermatotoxicology, 7th edn. Boca Raton, FL: CRC Press, 2008: 101-6.
44. Weltfriend S, Maibach HI. Irritant dermatitis: clinical heterogeneity and contributing factors. In: Zhai H, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology, 7th edn. Boca Raton, FL: CRC Press, 2008: 125-38.
45. Marzulli F, Maibach HI. Allergic contact dermatitis. In: Zhai H, Maibach HI, eds. Marzulli and Maibach's Dermatotoxicology, 7th edn. Boca Raton, FL: CRC Press, 2008: 155-8.
46. Grossberg G, Sadowsky C, Förstl H et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009; 23: 158-64.
47. Sadowsky CH, Dengiz A, Olin JT et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009; 24: 267-75.
48. Lefèvre G, Sȩdek G, Huang HL et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007; 47: 471-8.
49. Widman TJ, Oostman H, Storrs FJ. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis 2008; 19: 32-7.
50. Held E, Agner T. Effect of moisturizers on skin susceptibility to irritants. Acta Derm Venereol 2001; 81: 104-7.
51. Held E, Lund H, Agner T. Effect of different moisturizers on SLS-irritated human skin. Contact Dermatitis 2001; 44: 229-34.
52. Amkraut AA, Jordan WP, Taskovich L. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol 1996; 35: 27-31.
53. Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry 2007; 9: 113-21.
54. Winblad B, Brodaty H, Gauthier S et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 653-66.
55. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65.
56. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
57. Schmidt R, Alf C, Bancher C et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia. Neuropsychiatrie 2009; 23: 58-63.
58. Nagy B, Brennan A, Brandtmuller A et al. The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer's disease in the US. Poster presented at the American Association for Geriatric Psychiatry (AAGP), Orlando, FL, USA, 2008.
59. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16: 49-51.
60. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastimgine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231-9.